Applications

Conventional cancer models frequently fail to reproduce the complexity of the human tumor microenvironment, contributing to low clinical translation rates. Our organ-on-chip technology enables dynamic, human-relevant cancer models that integrate tissue architecture, mechanical forces, biochemical gradients, and multi-cellular interactions. These systems allow researchers to integrate tumor biology and evaluate therapeutic responses with greater physiological fidelity than static in vitro models or animal models.

Patient-specific variability is a defining feature of disease biology and therapeutic response, yet it is poorly captured by conventional preclinical models. By integrating patient-derived primary cells, organoids, and iPSC-derived tissues into organ-on-chip systems, our platform enables personalized testing that captures patient specific response and supports precision medicine.

Oxygen gradients and hypoxic microenvironments play a critical role in tissue physiology, disease progression, and therapeutic response. Traditional in vitro systems lack precise oxygen control, limiting their physiological relevance. Our organ-on-chip platform enables control of oxygen levels, allowing researchers to model hypoxia in both healthy and diseased tissues.

Reliable safety and efficacy assessment requires human-relevant models capable of capturing both acute and chronic toxicity. Our organ-on-chip platform enables physiologically relevant toxicology testing across multiple tissue types, improving detection of organ-specific toxicity and long-term exposure effects.

The human gut is a highly dynamic system governed by epithelial biology, mechanical forces, immune signaling, and microbial interactions. Conventional models struggle to replicate this complexity. Our organ-on-chip platform enables human-relevant gut models that integrate flow, shear stress, and biochemical gradients, supporting mechanistic and translational gut research.

The human microbiome is a key regulator of health, disease, and therapeutic response, yet remains difficult to model in vitro. Our organ-on-chip platform enables development of 3D tissue microenvironment with controlled flow, oxygen gradients, and hypoxic conditions, allowing physiologically relevant studies of host–microbe interactions.

Extracellular vesicles are emerging as key mediators of cell-to-cell communication in health and disease, influencing disease progression, immune regulation, and therapeutic response. Static culture systems inadequately capture EV transport, functional signaling, effect, and uptake within cell. With our platform, you can study EV-mediated signaling, transport, and functionality in controlled, dynamic, tissue specific microenvironment and explore their role in disease mechanisms and therapeutic development.

Biological barriers—including intestinal, pulmonary, blood–brain, and skin barriers—are essential for maintaining tissue homeostasis and regulating molecular transport. Barrier dysfunction underlies many diseases and influences drug efficacy and safety. Our organ-on-chip platform enables physiologically relevant barrier models under dynamic conditions.